Ann: Response to ASX Price Query, page-4

20190312 Paradigm BioPharmaceuticals (PAR) - Institutional and Commercial Marketing Presentation Final

• 1. Thanks PAR!!
     
     As previously reported, Paradigm Biopharmaceuticals Ltd (ASX: PAR) intends to report on thesecondary endpoints to its Phase 2b osteoarthritis randomised, double-blind, placebo-controlled, multicentred clinical trial (the Phase 2b OA Clinical Trial) in Q1/Q2 CY2019.

  
  IN addition to that mouth watering announcement (which they have noted as the reason for the speeding ticket)
  
  there is still all of this to come and more.........
  
  OA Phase 2b trial results released. Partnering Discussions Commenced

• Ø Release Secondary End-point data front the OA Phase 2b trial – Q1/Q2 2019

• Ø Potential to treat to MPS patients in Australia via the SAS – Q1/Q2 CY2019

• Ø Up to 50 ex-NFL players in the US to be treated with iPPS for OA pain - Potential forsignificant media attention if treatment is successful – Q1/Q2 CY2019

• Ø File IND for Phase 2/3 for Mucopolysaccharidosis (MPS) - Q2 CY2019

• Ø Further release of patients OA data under the TGA special access scheme

  throughout 2019

• Ø File TGA Provisional Approval to sell ZILUSOL (iPPS) in Australia – Q2 CY2019

• Ø Ross River Phase 2a (safety study) trial results release – Q2/Q3 CY2019

• Ø File IND and meet with FDA re Phase 3 trial in OA - Q3 CY2019

• Ø Possibility of being granted “Fast Track status” for Phase 3

  OA trial.

I just can't explain how excited i am. imagine how the board are feeling.

GLTA